Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress

被引:153
作者
Pangeni, Rudra [1 ]
Sharma, Shrestha [1 ]
Mustafa, Gulam [1 ]
Ali, Javed [1 ]
Baboota, Sanjula [1 ]
机构
[1] Hamdard Univ, Jamia Hamdard, Fac Pharm, Dept Pharmaceut, New Delhi 110062, India
关键词
resveratrol; nanoemulsion; high pressure homogenization; phase diagram; release study; DIRECT NOSE; BIOAVAILABILITY; PATHOGENESIS; DELIVERY;
D O I
10.1088/0957-4484/25/48/485102
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Resveratrol, a potent natural antioxidant, possesses a wide range of pharmacological activities, but its oral bioavailability is very low due to its extensive hepatic and presystemic metabolism. The aim of the present study was to formulate a kinetically stable nanoemulsion (o/w) using vitamin E:sefsol (1:1) as the oil phase, Tween 80 as the surfactant and Transcutol P as the co-surfactant for the better management of Parkinson's disease. The nanoemulsion was prepared by a spontaneous emulsification method, followed by high-pressure homogenization. Ternary phase diagrams were constructed to locate the area of nanoemulsion. The prepared formulations were studied for globule size, zeta potential, refractive index, viscosity, surface morphology and in vitro and ex vivo release. The homogenized formulation, which contained 150 mg ml(-1) of resveratrol, showed spherical globules with an average globule diameter of 102 +/- 1.46 nm, a least poly dispersity index of 0.158 +/- 0.02 and optimal zeta potential values of -35 +/- 0.02. The cumulative percentage drug release for the pre-homogenized resveratrol suspension, pre-homogenized nanoemulsion and post-homogenized nanoemulsion were 24.18 +/- 2.30%, 54.32 +/- 0.95% and 88.57 +/- 1.92%, respectively, after 24 h. The ex vivo release also showed the cumulative percentage drug release of 85.48 +/- 1.34% at 24 h. The antioxidant activity determined by using a DPPH assay showed high scavenging efficiency for the optimized formulation. Pharmacokinetic studies showed the higher concentration of the drug in the brain (brain/blood ratio: 2.86 +/- 0.70) following intranasal administration of the optimized nanoemulsion. Histopathological studies showed decreased degenerative changes in the resveratrol nanoemulsion administered groups. The levels of GSH and SOD were significantly higher, and the level of MDA was significantly lower in the resveratrol nanoemulsion treated group.
引用
收藏
页数:13
相关论文
共 31 条
[1]  
Ahmad MP, 2012, J CLIN DIAGN RES, V6, P542
[2]   SUPEROXIDE DISMUTASE - IMPROVED ASSAYS AND AN ASSAY APPLICABLE TO ACRYLAMIDE GELS [J].
BEAUCHAM.C ;
FRIDOVIC.I .
ANALYTICAL BIOCHEMISTRY, 1971, 44 (01) :276-&
[3]   Intranasal Delivery to the Central Nervous System: Mechanisms and Experimental Considerations [J].
Dhuria, Shyeilla V. ;
Hanson, Leah R. ;
Frey, William H., II .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (04) :1654-1673
[4]   Does levodopa slow or hasten the rate of progression of Parkinson's disease? [J].
Fahn, S .
JOURNAL OF NEUROLOGY, 2005, 252 (Suppl 4) :37-42
[5]   Development and characterization of a novel nystatin-loaded nanoemulsion for the buccal treatment of candidosis: Ultrastructural effects and release studies [J].
Fernandez Campos, Francisco ;
Calpena Campmany, Ana C. ;
Rodriguez Delgado, Gelen ;
Lopez Serrano, Olga ;
Clares Naveros, Beatriz .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (10) :3739-3752
[6]   Curcumin Enhances Oral Bioavailability and Anti-Tumor Therapeutic Efficacy of Paclitaxel upon Administration in Nanoemulsion Formulation [J].
Ganta, Srinivas ;
Devalapally, Harikrishna ;
Amiji, Mansoor .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (11) :4630-4641
[7]   Venlafaxine loaded chitosan NPs for brain targeting: Pharmacokinetic and pharmacodynamic evaluation [J].
Haque, Shadabul ;
Md, Shadab ;
Fazil, Mohammad ;
Kumar, Manish ;
Sahni, Jasjeet Kaur ;
Ali, Javed ;
Baboota, Sanjula .
CARBOHYDRATE POLYMERS, 2012, 89 (01) :72-79
[8]   Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism [J].
Hauser, David N. ;
Hastings, Teresa G. .
NEUROBIOLOGY OF DISEASE, 2013, 51 :35-42
[9]   Pathogenesis of Parkinson's Disease [J].
Hirsch, Etienne C. ;
Jenner, Peter ;
Przedborski, Serge .
MOVEMENT DISORDERS, 2013, 28 (01) :24-30
[10]   Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats [J].
Jin, Feng ;
Wu, Qin ;
Lu, Yuan-Fu ;
Gong, Qi-Hai ;
Shi, Jing-Shan .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 600 (1-3) :78-82